Deferred Tax Assets, Net of Valuation Allowance of BriaCell Therapeutics Corp. from 31 Jul 2021 to 31 Jul 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
BriaCell Therapeutics Corp. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Jul 2021 to 31 Jul 2025.
  • BriaCell Therapeutics Corp. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Jul 2025 was $4,101,290, a 4.9% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

BriaCell Therapeutics Corp. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $4,101,290 +$191,403 +4.9% 31 Jul 2025 10-K 16 Oct 2025 2025 FY
Q2 2024 $3,909,887 +$3,864,727 +8558% 31 Jul 2024 10-K 16 Oct 2025 2025 FY
Q2 2023 $45,160 -$3,210 -6.6% 31 Jul 2023 10-K 29 Oct 2024 2024 FY
Q2 2022 $48,370 -$10,960 -18% 31 Jul 2022 10-K 25 Oct 2023 2023 FY
Q2 2021 $59,330 31 Jul 2021 10-K 28 Oct 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.